X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11543) 11543
Magazine Article (15) 15
Publication (3) 3
Book Chapter (2) 2
Dissertation (2) 2
Conference Proceeding (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10921) 10921
deoxycytidine - analogs & derivatives (10662) 10662
deoxycytidine - administration & dosage (8401) 8401
female (7400) 7400
oncology (6517) 6517
male (6249) 6249
middle aged (6156) 6156
antineoplastic combined chemotherapy protocols - therapeutic use (5848) 5848
aged (5708) 5708
adult (4663) 4663
chemotherapy (4237) 4237
gemcitabine (4014) 4014
treatment outcome (3492) 3492
cancer (3174) 3174
capecitabine (2776) 2776
deoxycytidine - adverse effects (2740) 2740
fluorouracil - analogs & derivatives (2636) 2636
deoxycytidine - therapeutic use (2585) 2585
fluorouracil - administration & dosage (2469) 2469
antineoplastic combined chemotherapy protocols - adverse effects (2456) 2456
cisplatin - administration & dosage (2030) 2030
pancreatic neoplasms - drug therapy (1976) 1976
aged, 80 and over (1870) 1870
cisplatin (1746) 1746
antimetabolites, antineoplastic - administration & dosage (1712) 1712
drug administration schedule (1685) 1685
lung neoplasms - drug therapy (1678) 1678
therapy (1604) 1604
neoplasm staging (1546) 1546
animals (1498) 1498
pancreatic cancer (1480) 1480
pharmacology & pharmacy (1462) 1462
disease-free survival (1461) 1461
antineoplastic combined chemotherapy protocols - administration & dosage (1411) 1411
care and treatment (1382) 1382
survival (1374) 1374
survival rate (1361) 1361
carcinoma, non-small-cell lung - drug therapy (1331) 1331
antimetabolites, antineoplastic - therapeutic use (1329) 1329
trial (1313) 1313
pancreatic neoplasms - pathology (1287) 1287
carcinoma (1202) 1202
adenocarcinoma - drug therapy (1197) 1197
survival analysis (1183) 1183
combination (1173) 1173
medicine & public health (1159) 1159
research (1138) 1138
paclitaxel - administration & dosage (1126) 1126
organoplatinum compounds - administration & dosage (1100) 1100
prognosis (1092) 1092
breast neoplasms - drug therapy (1067) 1067
retrospective studies (1051) 1051
cell line, tumor (1026) 1026
mice (1019) 1019
dose-response relationship, drug (1005) 1005
deoxycytidine - pharmacology (993) 993
combined modality therapy (966) 966
paclitaxel (943) 943
5-fluorouracil (910) 910
antimetabolites, antineoplastic - adverse effects (892) 892
metastasis (887) 887
neoplasm metastasis (872) 872
drug therapy (861) 861
fluorouracil - adverse effects (844) 844
oxaliplatin (841) 841
antineoplastic agents (833) 833
adenocarcinoma (822) 822
analysis (804) 804
clinical trials (793) 793
antimitotic agents (790) 790
fluorouracil (785) 785
taxoids - administration & dosage (776) 776
lung neoplasms - pathology (774) 774
hematology, oncology and palliative medicine (772) 772
tumors (765) 765
disease progression (761) 761
follow-up studies (760) 760
carboplatin - administration & dosage (746) 746
docetaxel (741) 741
antineoplastic agents - administration & dosage (717) 717
phase-ii (717) 717
chemotherapy, adjuvant (706) 706
antineoplastic agents - therapeutic use (702) 702
radiotherapy (694) 694
breast neoplasms - pathology (688) 688
fluorouracil - therapeutic use (684) 684
cancer research (681) 681
colorectal neoplasms - drug therapy (674) 674
surgery (651) 651
kaplan-meier estimate (650) 650
adenocarcinoma - pathology (642) 642
time factors (642) 642
vinblastine - administration & dosage (634) 634
health aspects (628) 628
phase-ii trial (628) 628
toxicity (626) 626
administration, oral (612) 612
dosage and administration (610) 610
prospective studies (608) 608
camptothecin - analogs & derivatives (606) 606
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10875) 10875
Japanese (523) 523
Chinese (133) 133
French (108) 108
German (84) 84
Russian (45) 45
Spanish (37) 37
Italian (29) 29
Hungarian (15) 15
Portuguese (9) 9
Czech (6) 6
Dutch (5) 5
Polish (5) 5
Lithuanian (4) 4
Danish (2) 2
Hebrew (2) 2
Norwegian (2) 2
Romanian (2) 2
Bosnian (1) 1
Korean (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2429 - 2438
Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TREATMENT-NAIVE | PHARMACOKINETICS | RALTEGRAVIR | SAFETY | EFAVIRENZ | ADULTS | SINGLE-TABLET REGIMEN | PATIENTS 96-WEEK EFFICACY | COMBINATION | ADHERENCE | HIV-1 | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Atazanavir Sulfate | Adult | Female | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Antiretroviral drugs | Bone density | Pharmaceutical industry | Human immunodeficiency virus--HIV | Pneumonia | Laboratories | Ritonavir | Liver | Infections | Drug resistance | Evidence-based medicine | Hepatitis | Randomization | All terrain vehicles | Creatinine | Integrase | Data processing | Proteinase inhibitors | Behavior disorders | Ribonucleic acid--RNA | Patients | Cholesterol | Glomerular filtration rate | Protease inhibitors | Interactive systems
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie and the Associazione Italiana Oncologia Toracica and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 812 - 822
.... We aimed to show the superiority of the neoadjuvant administration of histotype-tailored regimen to standard chemotherapy... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CRITERIA | THERAPY | RECIST | CLINICAL-TRIAL | HIGH-GRADE | ONCOLOGY | DOSE ADJUVANT CHEMOTHERAPY | EXTREMITIES | TUMOR RESPONSE ASSESSMENT | IFOSFAMIDE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Trabectedin | Sarcoma - therapy | Young Adult | Neurilemmoma - therapy | Dioxoles - administration & dosage | Back | Adult | Neutropenia - chemically induced | Child | Extremities | Soft Tissue Neoplasms - therapy | Dacarbazine - administration & dosage | Thoracic Wall | Sarcoma, Synovial - therapy | Deoxycytidine - administration & dosage | Risk Factors | Docetaxel | Anemia - chemically induced | Etoposide - administration & dosage | Tetrahydroisoquinolines - administration & dosage | Thrombocytopenia - chemically induced | Abdominal Wall | Sarcoma - pathology | Leiomyosarcoma - therapy | Disease-Free Survival | Taxoids - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Neoadjuvant Therapy - methods | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Deoxycytidine - analogs & derivatives | Liposarcoma, Myxoid - therapy | Care and treatment | Anthracyclines | Sarcoma | Adjuvant treatment | Clinical trials | Product development | Standards | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2439 - 2448
...). On the basis of high virological efficacy and safety in prospective clinical trials,3-6 and ease of administration, this regimen is widely used and considered a gold standard... 
Internal Medicine | NON-INFERIORITY | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | RALTEGRAVIR | TREATMENT-EXPERIENCED PATIENTS | DISOPROXIL FUMARATE | ADULTS | ANTIRETROVIRAL THERAPY | SINGLE-TABLET REGIMEN | RILPIVIRINE | TREATMENT-NAIVE PATIENTS | Emtricitabine | HIV-1 | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Deoxycytidine - administration & dosage | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Adenine - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Organophosphonates - administration & dosage | Quinolones - administration & dosage | Adult | Female | HIV Infections - drug therapy | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Clinical trials | Antiretroviral drugs | Pharmaceutical industry | Human immunodeficiency virus--HIV | Creatinine | Integrase | Laboratories | Data processing | Infections | Nausea | Ribonucleic acid--RNA | Patients | Efavirenz | Evidence-based medicine | Dreams | Sleep disorders | Hepatitis | Dyspnea | Inhibitors | Protease inhibitors | Insomnia | Suicides & suicide attempts
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 6, pp. 509 - 518
... – 4 On the basis of these observations, in July 2012 the Food and Drug Administration approved daily treatment with Truvada for the prevention of HIV-1 acquisition, and the Centers for Disease Control and Prevention has issued . . . 
TRIALS | MEDICINE, GENERAL & INTERNAL | TRANSMISSION | ANTIRETROVIRAL PROPHYLAXIS | MICROBICIDE | PREVENTION | ADHERENCE | GEL | HIV Infections - prevention & control | Humans | Middle Aged | Drug Resistance, Viral | Administration, Intravaginal | Deoxycytidine - blood | Adenine - blood | Tenofovir | Young Adult | Adenine - adverse effects | Adult | Deoxycytidine - adverse effects | Female | Organophosphonates - blood | Surveys and Questionnaires | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | HIV Seropositivity | Administration, Oral | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Anti-Retroviral Agents - adverse effects | Organophosphonates - adverse effects | Africa South of the Sahara | Adenine - administration & dosage | Pre-Exposure Prophylaxis | Organophosphonates - administration & dosage | Medication Adherence | Anti-Retroviral Agents - administration & dosage | Adolescent | HIV Infections - complications | Deoxycytidine - analogs & derivatives | Women | Care and treatment | HIV infection in women | Dosage and administration | HIV infection | Health aspects | Risk factors | Intervention | Creatinine | Antiretroviral drugs | Motivation | Human immunodeficiency virus--HIV | Prophylaxis | Vagina | Infections | Preventive medicine
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
Journal of controlled release, ISSN 0168-3659, 2016, Volume 229, pp. 183 - 191
Functional nanocarriers capable of transporting high drug contents without premature leakage and to controllably deliver several drugs are needed for better... 
Mesoporous silica nanoparticles | Multi-drug delivery | Bovine serum albumin | Gold nanoclusters | Cancer | BRIDGED SILSESQUIOXANE NANOPARTICLES | VITRO | PEGYLATED LIPOSOMAL DOXORUBICIN | COMBINATION | CHEMISTRY, MULTIDISCIPLINARY | GEMCITABINE | BREAST-CANCER | NANOCLUSTERS | RESPONSIVE CONTROLLED-RELEASE | FLUORESCENT-PROBES | PHARMACOLOGY & PHARMACY | ORGANOSILICA NANOPARTICLES | Silicon Dioxide - administration & dosage | Deoxycytidine - chemistry | Gold - administration & dosage | Nanocomposites - chemistry | Nanoparticles - chemistry | Serum Albumin, Bovine - administration & dosage | Humans | Drug Carriers - administration & dosage | Doxorubicin - chemistry | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Serum Albumin, Bovine - chemistry | Doxorubicin - administration & dosage | Gold - chemistry | A549 Cells | Cell Line | Deoxycytidine - administration & dosage | Silicon Dioxide - chemistry | Antineoplastic Agents - chemistry | Neoplasms - diagnostic imaging | Neoplasms - drug therapy | Drug Liberation | Nanoparticles - administration & dosage | Porosity | Deoxycytidine - analogs & derivatives | Nanocomposites - administration & dosage | Nanoparticles | Drugs | Albumin | Precious metal products | Silica | Tumors | Drug delivery systems | Anthracyclines | Pharmaceutical industry | Vehicles
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 388, Issue 10039, pp. 73 - 85
Summary Pancreatic cancer is a highly lethal disease, for which mortality closely parallels incidence. Most patients with pancreatic cancer remain asymptomatic... 
Internal Medicine | PHASE-III TRIAL | ADJUVANT CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | DIFFERENTIAL-DIAGNOSIS | FINE-NEEDLE-ASPIRATION | INCREASED RISK | AUTOIMMUNE PANCREATITIS | EARLY MANIFESTATIONS | CLASSIFICATION-SYSTEM | PREOPERATIVE EVALUATION | INTRAEPITHELIAL NEOPLASIA | Leucovorin - administration & dosage | Endosonography | Pancreatic Neoplasms - diagnosis | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Tumor Suppressor Protein p53 - genetics | Carcinoembryonic Antigen - metabolism | Carcinoma, Pancreatic Ductal - genetics | Neoplasms, Cystic, Mucinous, and Serous - genetics | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Smad4 Protein - genetics | Carcinoma, Pancreatic Ductal - diagnosis | Camptothecin - administration & dosage | Paclitaxel - administration & dosage | Endoscopic Ultrasound-Guided Fine Needle Aspiration | Camptothecin - analogs & derivatives | Deoxycytidine - administration & dosage | Pancreatectomy | Albumins - administration & dosage | Pancreatic Neoplasms - genetics | Carcinoma, Pancreatic Ductal - therapy | Genes, p16 | CA-19-9 Antigen - metabolism | Neoplasms, Cystic, Mucinous, and Serous - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Cystic, Mucinous, and Serous - diagnosis | Deoxycytidine - analogs & derivatives | Pancreatic Neoplasms - therapy | Medical colleges | Ultrasound imaging | Oncology, Experimental | Mortality | Japan | Pancreatitis | Adjuvant treatment | Leucovorin | Research | Pancreatic cancer | Diagnosis | Tumor proteins | Health aspects | Cancer | Pathology | Chemotherapy | Medical prognosis | Metastasis | Health risk assessment | Cancer therapies | Tumors
Journal Article